The introduction of the A6E mutation to the ASNS gene could be an alternative approach to impede the attempt of cancer cells to stimulate the expression of ASNS, such that the ALL patients would not develop any resistance to the asparaginase treatment. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.